Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic ...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.